journal
https://read.qxmd.com/read/37138373/impact-of-obesity-surgery-on-tyrosine-kinase-inhibitor-responses-and-survival-outcomes-in-patients-with-chronic-myeloid-leukemia-further-data-are-still-warranted
#21
LETTER
https://read.qxmd.com/read/37132124/erratum-to-concordance-in-postsurgical-radioactive-iodine-therapy-recommendations-between-watson-for-oncology-and-clinical-practice-in-patients-with-differentiated-thyroid-carcinoma
#22
https://read.qxmd.com/read/37129197/safety-tolerability-and-clinical-activity-of-selinexor-in-combination-with-pembrolizumab-in-treatment-of-metastatic-non-small-cell-lung-cancer
#23
JOURNAL ARTICLE
Mehmet Altan, Janet Tu, Denái R Milton, Bulent Yilmaz, Yanyan Tian, Frank V Fossella, Frank E Mott, George R Blumenschein, Bettzy Stephen, Daniel D Karp, Funda Meric-Bernstam, John V Heymach, Aung Naing
BACKGROUND: In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities. Here, clinical safety and early efficacy data are presented on the combination of pembrolizumab and an oral selective nuclear export inhibitor, selinexor, for the treatment of metastatic non-small cell lung cancer (mNSCLC). METHODS: The primary objective of this prospective investigator-initiated study was to determine the safety and tolerability of selinexor in combination with pembrolizumab in patients with mNSCLC...
May 2, 2023: Cancer
https://read.qxmd.com/read/37126202/cancer-turns-75
#24
EDITORIAL
Suresh S Ramalingam
No abstract text is available yet for this article.
May 1, 2023: Cancer
https://read.qxmd.com/read/37118834/association-of-polypharmacy-with-all-cause-mortality-and-adverse-events-among-elderly-colorectal-cancer-survivors
#25
JOURNAL ARTICLE
Dong-Woo Choi, Hyejung Kang, Hyun-Soo Zhang, Hoyol Jhang, Wonjeong Jeong, Sohee Park
BACKGROUND: The risk of inappropriate drug exposure in elderly colorectal cancer (CRC) survivors after the initial cancer treatment has not been well studied. This study investigated the association of polypharmacy (PP) with overall survival, hospitalization, and emergency room (ER) visits among older CRC survivors. METHODS: A retrospective cohort study was conducted using the Korean National Health Insurance claims data follow-up from 2002 to 2017. Participants comprised those aged ≥65 years who were hospitalized with a diagnosis of CRC received cancer treatment and survived at least 2 years from the initial CRC diagnosis between 2003 and 2012...
April 28, 2023: Cancer
https://read.qxmd.com/read/37106560/increased-survival-of-women-with-luminal-breast-cancer-and-progesterone-receptor-immunohistochemical-expression-of-greater-than-10
#26
LETTER
Steven Lehrer, Peter H Rheinstein
No abstract text is available yet for this article.
April 27, 2023: Cancer
https://read.qxmd.com/read/37106558/reply-to-increased-survival-of-women-with-luminal-breast-cancer-and-progesterone-receptor-immunohistochemical-expression-of-greater-than-10
#27
LETTER
Ayat G Lashen, Michael S Toss, Emad A Rakha
No abstract text is available yet for this article.
April 27, 2023: Cancer
https://read.qxmd.com/read/37185873/obesity-in-adult-acute-myeloid-leukemia-is-not-associated-with-inferior-response-or-survival-even-when-dose-capping-anthracyclines-an-ecog-acrin-analysis
#28
JOURNAL ARTICLE
James M Foran, Zhuoxin Sun, Catherine Lai, Hugo F Fernandez, Larry D Cripe, Rhett P Ketterling, Janis Racevskis, Selina M Luger, Elisabeth Paietta, Hillard M Lazarus, Yanming Zhang, John M Bennett, Ross L Levine, Jacob M Rowe, Mark R Litzow, Martin S Tallman
BACKGROUND: Obesity (body mass index [BMI] ≥30 kg/m2 ) is an important epidemiological risk factor for developing acute myeloid leukemia (AML). Therefore, the authors studied the association of obesity with clinical and genetic phenotype and its impact on outcome in adults with AML. METHODS: The authors analyzed BMI in 1088 adults who were receiving intensive remission induction and consolidation therapy in two prospective, randomized therapeutic clinical trials of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network: E1900 (ClinicalTrials...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096888/plasma-levels-of-interleukin-6-mediate-neurocognitive-performance-in-older-breast-cancer-survivors-the-thinking-and-living-with-cancer-study
#29
JOURNAL ARTICLE
Jeanne S Mandelblatt, Brent J Small, Xingtao Zhou, Zev M Nakamura, Harvey J Cohen, Tim A Ahles, Jaeil Ahn, Traci N Bethea, Martine Extermann, Deena Graham, Claudine Isaacs, Paul B Jacobsen, Heather S L Jim, Brenna C McDonald, Sunita K Patel, Kelly E Rentscher, James C Root, Andrew J Saykin, Danielle B Tometich, Kathleen Van Dyk, Wanting Zhai, Elizabeth C Breen, Judith E Carroll
BACKGROUND: Immune activation/inflammation markers (immune markers) were tested to explain differences in neurocognition among older breast cancer survivors versus noncancer controls. METHODS: Women >60 years old with primary breast cancer (stages 0-III) (n = 400) were assessed before systemic therapy with frequency-matched controls (n = 329) and followed annually to 60 months; blood was collected during annual assessments from 2016 to 2020...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096827/neighborhood-attributes-and-cardiovascular-disease-risk-in-breast-cancer-survivors-the-pathways-study
#30
JOURNAL ARTICLE
Shannon M Conroy, Julie Von Behren, Marilyn L Kwan, Lawrence H Kushi, Mi-Ok Kim, Carlos Iribarren, Janise M Roh, Cecile A Laurent, Catherine Thomsen, Janet N Chu, Heather Greenlee, Scarlett Lin Gomez, Salma Shariff-Marco
BACKGROUND: Breast cancer survivors are at a higher risk of cardiovascular disease (CVD) morbidity and mortality compared with the general population. The impact of objective social and built neighborhood attributes on CVD risk in a cohort of female breast cancer survivors was examined. METHODS: The 3975 participants came from the Pathways Study, a prospective cohort of women with invasive breast cancer from an integrated health care system in northern California...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096803/increased-plasma-levels-of-monocyte-chemoattractant-protein-1-in-patients-with-hepatitis-b-virus-pre-s2-gene-deletion-mutation-predict-a-higher-risk-of-hepatocellular-carcinoma-recurrence-after-curative-surgical-resection
#31
JOURNAL ARTICLE
Long-Bin Jeng, Tsai-Chung Li, John Wang, Chiao-Fang Teng
BACKGROUND: Despite resection surgery as a curative therapy for hepatocellular carcinoma (HCC), the high rate of postoperative HCC recurrence remains a big challenge for patient survival. Chronic hepatitis B virus (HBV) infection is the most important risk factor for HCC. Deletion mutation in the HBV pre-S2 gene leads to expression of an essential viral oncoprotein called pre-S2 mutant and represents an independent prognostic biomarker for HCC recurrence after curative surgical resection...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096763/utility-of-cyp2d6-copy-number-variants-as-prognostic-biomarker-in-localized-anal-squamous-cell-carcinoma
#32
JOURNAL ARTICLE
Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Miguel Nogué, Isabel Busquier, Fernando Arias, Fernando López-Campos, Ana Fernández-Montes, Ana Ruiz, Concepción Velázquez, Celia Martín-Bravo, Elisabeth Pérez-Ruiz, Elena Asensio, Xavier Hernández-Yagüe, Aline Rodrigues, Ismael Ghanem, Rocío López-Vacas, Ahmed Hafez, Pedro Arias, Irene Dapía, Mario Solís, Antje Dittmann, Ricardo Ramos, Carlos Llorens, Joan Maurel, Ángel Campos-Barros, Juan Ángel Fresno Vara, Jaime Feliu
BACKGROUND: Anal squamous cell carcinoma (ASCC) is an infrequent tumor whose treatment has not changed since the 1970s. The aim of this study is the identification of biomarkers allowing personalized treatments and improvement of therapeutic outcomes. METHODS: Forty-six paraffin tumor samples from ASCC patients were analyzed by whole-exome sequencing. Copy number variants (CNVs) were identified and their relation to disease-free survival (DFS) was studied and validated in an independent retrospective cohort of 101 ASCC patients from the Multidisciplinary Spanish Digestive Cancer Group (GEMCAD)...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096747/detection-of-multiple-types-of-cancer-driver-mutations-using-targeted-rna-sequencing-in-nonsmall-cell-lung-cancer
#33
JOURNAL ARTICLE
Sheng Ju, Zihan Cui, Yuanyuan Hong, Xiaoqing Wang, Weina Mu, Zhuolin Xie, Xuexia Zeng, Lin Su, Xiaojing Lin, Zhuo Zhang, Qi Zhang, Xiaofeng Song, Songxia You, Ruixin Chen, Weizhi Chen, Chun Xu, Jun Zhao
BACKGROUND: DNA-based next-generation sequencing has been widely used in the selection of target therapies for patients with nonsmall cell lung cancer (NSCLC). RNA-based next-generation sequencing has been proven to be valuable in detecting fusion and exon-skipping mutations and is recommended by National Comprehensive Cancer Network guidelines for these mutation types. METHODS: The authors developed an RNA-based hybridization panel targeting actionable driver oncogenes in solid tumors...
April 25, 2023: Cancer
https://read.qxmd.com/read/37096746/rna-sequencing-steps-toward-the-first-line
#34
EDITORIAL
Theresa A Boyle, Aaron D Bossler
DNA is the sequence that codes for proteins. Messenger RNA is transcribed from the DNA sequence of genes and translated into protein. It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality. DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene. DNA sequencing is often used clinically to predict how DNA changes might affect proteins. Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products...
April 25, 2023: Cancer
https://read.qxmd.com/read/37089083/vitamin-d-supplementation-increases-objective-response-rate-and-prolongs-progression-free-time-in-patients-with-advanced-melanoma-undergoing-anti-pd1-therapy
#35
JOURNAL ARTICLE
Łukasz Galus, Michał Michalak, Mateusz Lorenz, Renata Stoińska-Swiniarek, Daria Tusień Małecka, Agnieszka Galus, Tomasz Kolenda, Ewa Leporowska, Jacek Mackiewicz
BACKGROUND: Vitamin D3 is a prohormone with pleiotropic effects, including modulating the functions of the immune system and may affect the effectiveness of anti-PD-1 treatment in patients with cancer. According to the literature, the potential mechanism of vitamin D's influence on the effectiveness of therapy is most likely related to the amount and activity of tumor-infiltrating lymphocytes. There are data showing the effect of vitamin D on cells regulating the activity of CD8 lymphocytes...
April 24, 2023: Cancer
https://read.qxmd.com/read/37084075/metastatic-adult-type-non-rhabdomyosarcoma-soft-tissue-sarcomas-in-children-and-adolescents-a-cohort-study-from-the-european-paediatric-soft-tissue-sarcoma-study-group
#36
JOURNAL ARTICLE
Andrea Ferrari, Daniel Orbach, Michela Casanova, Max M van Noesel, Pablo Berlanga, Bernadette Brennan, Nadege Corradini, Reineke A Schoot, Gema L Ramirez-Villar, Lisa Lyngsie Hjalgrim, Rita Alaggio, Gabriela Guillen Burrieza, Akmal Safwat, Alison L Cameron, Rick R van Rijn, Veronique Minard-Colin, Ilaria Zanetti, Gianni Bisogno, Julia C Chisholm, Johannes H M Merks
BACKGROUND: Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined. METHODS: This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group...
April 21, 2023: Cancer
https://read.qxmd.com/read/37082910/oncofertility-related-psycho-educational-therapy-for-young-adult-patients-with-breast-cancer-and-their-partners-randomized-controlled-trial
#37
JOURNAL ARTICLE
Tomoe Koizumi, Yodo Sugishita, Yuki Suzuki-Takahashi, Kazuko Nara, Tomoko Miyagawa, Misako Nakajima, Kouhei Sugimoto, Manabu Futamura, Tatsuro Furui, Yasushi Takai, Hiroshi Matsumoto, Hideko Yamauchi, Shinji Ohno, Akemi Kataoka, Kiyotaka Kawai, Eisuke Fukuma, Hiroko Nogi, Koichiro Tsugawa, Nao Suzuki
BACKGROUND: A couples' psycho-educational program called Oncofertility! Psycho-Education and Couple Enrichment (O!PEACE) therapy was created and its effect when provided before cancer treatment was examined. METHODS: This multicenter randomized controlled trial with nonmasking, parallel two-group comparison enrolled women aged 20 to 39 years with early-stage breast cancer and their partners. They were randomly assigned to receive O!PEACE (37 couples) or usual care (37 couples)...
April 21, 2023: Cancer
https://read.qxmd.com/read/37081639/intersectional-disparities-in-climate-vulnerability-and-cancer-risk
#38
JOURNAL ARTICLE
Kilan C Ashad-Bishop, Mayra Cruz, Zinzi D Bailey, Erin K Kobetz
Despite significant progress in the early detection, treatment, and survivorship of cancer in recent decades, cancer disparities continue to plague segments of the US population. Many of these cancer disparities, especially those among historically marginalized racial and ethnic groups and those with lower socioeconomic resources, are caused and perpetuated by social and structural barriers to health. These social and structural barriers, which operate beyond the framework of cancer control, also systematically increase vulnerability to and decrease adaptive capacity for the deleterious effects of anthropogenic climate change...
April 20, 2023: Cancer
https://read.qxmd.com/read/37081608/pediatric-phase-2-trial-of-a-wee1-inhibitor-adavosertib-azd1775-and-irinotecan-for-relapsed-neuroblastoma-medulloblastoma-and-rhabdomyosarcoma
#39
JOURNAL ARTICLE
Kristina A Cole, Heba Ijaz, Lea F Surrey, Mariarita Santi, Xiaowei Liu, Charles G Minard, John M Maris, Stephan Voss, Joel M Reid, Elizabeth Fox, Brenda J Weigel
BACKGROUND: Inhibition of the WEE1 kinase by adavosertib (AZD1775) potentiates replicative stress from genomic instability or chemotherapy. This study reports the pediatric solid tumor phase 2 results of the ADVL1312 trial combining irinotecan and adavosertib. METHODS: Pediatric patients with recurrent neuroblastoma (part B), medulloblastoma/central nervous system embryonal tumors (part C), or rhabdomyosarcoma (part D) were treated with irinotecan and adavosertib orally for 5 days every 21 days...
April 20, 2023: Cancer
https://read.qxmd.com/read/37081596/pediatric-ddr-inhibitor-combinations-are-wee1-there-yet
#40
EDITORIAL
Emily K Slotkin, Michael V Ortiz, Julia L Glade Bender
No abstract text is available yet for this article.
April 20, 2023: Cancer
journal
journal
20067
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.